Search Result

Results for "

bioenergetics

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (4) Bacterial (2) CFTR (3) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (6) Oxidative Phosphorylation (1) P-glycoprotein (3) PDHK (2) Potassium Channel (3) Reactive Oxygen Species (1) ROCK (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (2) Metabolic Disease (4) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15206

Glibenclamide Maximum Cited Publications 18 Publications Verification Glyburide	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glibenclamide (Glyburide) is an orally active ATP-sensitive K ⁺ channel (K_ATP) inhibitor and can be used for the research of diabetes and obesity . Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of K_ATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR) . Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability . Glibenclamide can induce autophagy .

HY-W017540

Cyclocreatine 1 Publications Verification	Others	Cardiovascular Disease
Cyclocreatine is a Creatine analogue and acts as a potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine crosses membranes, enters the brain, and can be phosphorylated and dephosphorylated by creatine kinases .

HY-134832

Mito-LND 1 Publications Verification Mito-Lonidamine	Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species Autophagy	Cancer
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells .

HY-N3383

Ligustroside Ligstroside	Mitochondrial Metabolism	Neurological Disease
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

HY-157538

PDK4-IN-2	PDHK	Cardiovascular Disease
PDK4-IN-2 (compound 8) is a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC₅₀ of 46 µM. PDK4-IN-2 improves ejection fraction of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle .

HY-162142

BB2-50F	Bacterial	Infection
BB2-50F is a potent and multi-targeting bioenergetic bactericidal inhibitor of *M. tuberculosis* and can sterilizes replicating and non-replicating *M. tuberculosis. BB2-50F inhibits succinate oxidation, decreases the activity of the tricarboxylic acid (TCA) cycle, and results in succinate secretion from M. tuberculosis*.

HY-101998

CTP inhibitor

Others Metabolic Disease

CTP inhibitor is a potent and selective CTP inhibitor. CTP inhibitor inhibits the plasma membrane citrate transporter (PMCT) .

CTP inhibitor	Others	Metabolic Disease
CTP inhibitor is a potent and selective CTP inhibitor. CTP inhibitor inhibits the plasma membrane citrate transporter (PMCT) .

HY-156109

PDK-IN-2	PDHK Mitochondrial Metabolism	Cancer
PDK-IN-2 (Compound 1F) is a PDK inhibitor (IC₅₀: 68 nM). PDK-IN-2 inhibits the cellular expression of PDK1 and PDK4. PDK-IN-2 enhances mitochondrial bioenergetics, attenuates glycolytic phenotypes, and induces cell apoptosis in the mitochondrial pathway. PDK-IN-2 inhibits tumor growth in 4T1 syngeneic mice model .

HY-15206S

Glyburide-d11	Isotope-Labeled Compounds Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S1

Glyburide-d3 Glyburide-d₃	Potassium Channel Mitochondrial Metabolism Autophagy CFTR P-glycoprotein	Metabolic Disease
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-162028

GaMF1.39	Bacterial	Infection
GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors .

HY-110339

RKI-1447 dihydrochloride 2 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective ROCK inhibitor with IC₅₀s of 14.5 and 6.2 nM for ROCK1 and ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis .

eNOS pT495 decoy peptide	Peptides	Others
eNOS pT495 decoy peptide is a specific decoy peptide to prevent T495 phosphorylation reduced eNOS uncoupling and mitochondrial redistribution. eNOS pT495 decoy peptide is used in ventilator-induced lung injury research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3383

Ligustroside Ligstroside	Monophenols Iridoids Oleaceae Ligustrum japonicum Thunb. Terpenoids Source classification Phenols Plants	Mitochondrial Metabolism
Ligustroside (Ligstroside), a secoiridoid derivative, has outstanding performance on mitochondrial bioenergetics in models of early Alzheimer's disease (AD) and brain ageing by mechanisms that may not interfere with Aβ production. Ligustroside significantly inhibits nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages .

Cat. No.	Product Name	Chemical Structure

HY-15206S1

Glyburide-d3
Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Glyburide-d3

Glyburide-d₃ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

HY-15206S

Glyburide-d11
Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Glyburide-d11

Glyburide-d₁₁ is the deuterium labeled Glibenclamide. Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity[1]. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR)[3]. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability[4]. Glibenclamide can induce autophagy[5].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks